Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of TGF signal inhibitor in preventing and treating cancerous anemia

A technology of signal suppression and cancerous anemia, which is applied in the field of biomedicine, can solve the problems of unclear pathogenesis and effects, and achieve the effect of alleviating or alleviating the symptoms of cancerous anemia, improving the treatment effect, and maintaining bone homeostasis

Inactive Publication Date: 2020-08-11
SUN YAT SEN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of TGFβ in the pathogenesis, occurrence and development of cancerous anemia has not been studied clearly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TGF signal inhibitor in preventing and treating cancerous anemia
  • Application of TGF signal inhibitor in preventing and treating cancerous anemia
  • Application of TGF signal inhibitor in preventing and treating cancerous anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1 Culture of Lewis Lung Cancer LLC Cells and Construction of Tumor-bearing Mouse Model

[0067] 1.1 LLC cell culture: LLC cells (ATCC #CRL-1642) were cultured with DMEM basal medium (containing 10% fetal bovine serum) for later use.

[0068] 1.2 Raising method for mice: feed mice with conventional mouse feed (protein content 20-25wt%, fat content 5%-10wt%, crude fiber content 3-5wt%).

[0069] 1.3 Construction of mouse tumor-bearing model

[0070] Male C57BL / 6 mice (purchased from the Institute of Model Animals, Nanjing University) with a weight difference of no more than 2 g at the age of 8 weeks were taken, and the mice were randomly divided into a control group and an LLC cell transplantation group, with 6 mice in each group. About 4 × 10 6 LLC cells, the experimental process was carried out in a clean bench, pay attention to aseptic operation. The mice in the control group did not receive any treatment. The day of LLC cell transplantation (ie, tumor-bear...

Embodiment 2

[0071] Example 2 Evaluation of hematopoietic function in tumor-bearing mice

[0072] 2.1 Routine blood test in mice

[0073] The 21-day-old tumor-bearing mice and the control mice were taken, anesthetized with 10% chloral hydrate, and the blood samples were extracted from the inferior vena cava of the mice. The blood sample was immediately tested for the number of red blood cells, the level of hemoglobin and the average concentration of red blood cells with a blood routine analyzer. Such as figure 1 As shown in middle panel A-panel C, compared with the control group, the number of red blood cells, hemoglobin level and average hemoglobin concentration of red blood cells in the tumor-bearing mice were significantly reduced, suggesting that the tumor-bearing mice had symptoms of anemia.

[0074] 2.2 Differentiation detection of mouse erythroid progenitor cells

[0075] The 21-day-old tumor-bearing mice and the control mice were taken, anesthetized with 10% chloral hydrate, th...

Embodiment 3

[0076] Example 3 Detection of TGF signaling pathway in tumor-bearing mice

[0077] The 21-day-old tumor-bearing mice and the control mice were taken, anesthetized with 10% chloral hydrate, and the femurs of the mice were separated. After fixed overnight in 4% paraformaldehyde and decalcified with 10% EDTA for 2 weeks, frozen sections were performed. Fluorescently label TGFβ by DAPI, as figure 2 As shown in middle panel A, an increase in the level of TGFβ in the bone marrow microenvironment of tumor-bearing mice can be observed.

[0078] The cell suspension obtained in 2.2 was extracted with RIPA lysate, electrophoresed by SDS-PAGE, transferred to membrane, incubated with Smad2 / 3 and p-Smad2 / 3 antibodies, and developed to obtain figure 2 In the middle panel B, the level of p-Smad2 / 3 in the bone marrow microenvironment of tumor-bearing mice can be observed to increase, suggesting that the TGF signaling pathway is activated in the bone marrow microenvironment of tumor-bearing...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a TGF signal inhibitor in preparation of a medicine for treating and / or preventing cancer anemia. Researches show that the TGF signal inhibitor has an obviousprevention and treatment effect on cancer anemia, and the TGF signal inhibitor is mainly used for reducing bone resorption, so as to facilitate maintaining of a bone steady state, improving hematopoietic microenvironment and delaying occurrence of cancer anemia; and the TGF signal inhibitor is also beneficial to relieving or alleviating cancer anemia symptoms of patients and improving the tumor treatment effect. Therefore, the TGF signal inhibitor has a good application value in the aspects of treating and / or preventing cancer anemia and improving the tumor treatment effect.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of TGF signal inhibitors in the preparation of medicines for treating and / or preventing cancerous anemia, and the medicines for treating and / or preventing cancerous anemia. Background technique [0002] Cancerous anemia is a common concomitant symptom of cancer patients, manifested as a progressive decrease in hemoglobin level and a decrease in the number of red blood cells. Anemia occurs in at least 30% of cancer patients, and the symptoms gradually worsen as the tumor progresses. Patients with cancerous anemia are usually accompanied by fatigue, lethargy, dyspnea, anorexia, and gradual deterioration of cognitive function. These symptoms significantly affect the quality of life of the patient, and lead to poor tolerance of the patient's tumor treatment, weakening the treatment of the tumor Effect. Therefore, the treatment of cancerous anemia pla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/4439A61P35/00A61P7/06
CPCA61K31/4439A61K45/06A61P7/06A61P35/00
Inventor 项鹏汪建成王博彦
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com